Parameters |
| n(%) | P value |
Age Group (years): | 18 - 28 | 63 (14.6) | 0.00 |
29 - 39 | 196 (45.4) | ||
40 - 49 | 122 (28.2) | ||
50 - 59 | 47 (10.9) | ||
≥60 | 4 (0.9) | ||
Total |
| 432 (100) |
|
Mean Age | 38.15 ± 9.5 Years |
|
|
Gender | Male | 184 (42.6) | 0.002 |
Female | 248 (57.4) | ||
Total |
| 432 (100) |
|
WHO Clinical Staging | Stage I | 163 (37.7) | 0.00 |
Stage II | 132 (30.6) | ||
Stage III | 95 (22.2) | ||
Stage IV | 42 (9.7) | ||
CD4+ve T Cell Count | 0 - 99 | 266 (62) | 0.000 |
100 - 199 | 100 (23.3) | ||
≥200 | 63 (14.4) | ||
Mean | 112 |
| Range (6 - 1264) |
Median | 74 |
|
|
Cryptococcal Antigen Positivity | Negative | 425 (98.4) | 0.000 |
Positive | 7 (1.6) |